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Some vaccines show poor efﬁcacy in tropical countries. Within a birth cohort in Uganda, we investigated
factors that might inﬂuence responses to BCG and tetanus immunisation. Whole blood assay responses
to crude culture ﬁltrate proteins of Mycobacterium tuberculosis (cCFP)) and tetanus toxoid (TT) were
examined among 1506 and 1433 one-year-olds, respectively.MaternalMansonella perstans infectionwas
associated with higher interleukin (IL)-10 responses to both immunogens but no reduction in gamma
interferon (IFN-), IL-5 and IL-13 responses; other maternal helminth infections showed little effect.CG
etanus
mmunisation
Tetanus immunisation during pregnancy was associated with higher infant responses to TT; maternal
BCG scar (from past immunisation) with lower infant IL-5 and IL-13 responses to cCFP. IFN-, IL-5 and
IL-13 to TT were reduced in HIV-exposed-uninfected infants; infant malaria and HIV were associated
with lower IFN-, IL-5 and IL-13 responses to both immunogens. We conclude that maternal helminth
infections are unlikely to explain poor vaccine efﬁcacy in the tropics. Effects ofmaternal immunisation on
nes sh
isati
 infant responses to vacci
to effectiveness of immun
. Introduction
Immunisation is key to the control of infectious diseases but
he efﬁcacy of some vaccines is poor in tropical, developing
ountries, where they are most needed [1]. In particular, Bacille
almette-Guérin (BCG) immunisation has over 70% efﬁcacy against
uberculosis in temperate countries, but lowefﬁcacy in tropical set-
ings [2,3]. The reasons for this need to be understood. Tuberculosis
emains a major cause of global morbidity and mortality [4]; effec-
ive immunisation could revolutionise tuberculosis control and
ew vaccines are being developed [5], but new vaccines may be
nﬂuenced by the same factors that inhibit the response to BCG
n the tropics. Understanding these factors may allow the develop-
entof interventions to improve theeffectivenessof immunisation
rogrammes. Several hypotheses as to the nature of these fac-
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Open access under CC BY license. ould be explored. Prevention of infant malaria and HIV could contribute
on programmes.
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tors have been advanced. Genetic differences between populations
may be important, but efﬁcacy in migrant populations tends to
approach that observed in the native populations of the adoptive
country [3,6,7]; differences in BCG strains used have been con-
sidered, but trials using the same source of BCG have also shown
differences in efﬁcacy by latitude [3]; effects of vaccine exposure
to sunlight and breakdown in the cold chain have been consid-
ered, but are unlikely to explain low efﬁcacy in carefully conducted
trials. Two outstanding hypotheses particularly remain to be con-
sidered.
One of these is that exposure to environmental mycobacte-
ria, which is more common in the tropics, masks, or blocks, the
response to BCG in this setting. Early evidence for this hypothe-
sis [3] has been supported by subsequent studies showing higher
levels of sensitisation to mycobacterial antigens in unvaccinated
Malawian compared to British populations, and smaller increases
in the gamma interferon (IFN-) response following BCG inMalaw-
ian than in British adolescents [8]. However, vaccine-induced
Open access under CC BY license.responses were not directly related to prior sensitisation to envi-
ronmental mycobacteria [9], suggesting that other factors might
play a role. Also, differences in response to BCG immunisationwere
demonstrated between Malawian and British infants at an age too
young for effects to be explained by direct exposure to environ-
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ental organisms [10]; thus prenatal exposures are likely to be
mportant.
A second hypothesis is that chronic helminth infections inﬂu-
nce responses to BCG and other vaccines [11]. Helminths elicit
trong type 2 and regulatory immune responses [12]; these effects
an “spill over” to inﬂuence responses to unrelated antigens and
an inhibit type 1 responses that are a component of the protec-
ive response against tuberculosis [13–16]. De-worming prior to
CG immunisation can improve the induced response to puriﬁed
rotein derivative of Mycobacterium tuberculosis [17]. Also, sensi-
isation to helminth antigens in utero may be associated with a
witch to a type 2 response proﬁle following BCG immunisation at
irth, again emphasising the potential role of exposures very early
n life [18].
In response to this last observation, we set up a randomised,
ontrolled trial of anthelminthic treatment during pregnancy to
nvestigate the hypothesis that exposure to, and treatment of,
aternal worms during pregnancy would inﬂuence the infant
esponse to BCG and other immunisations [19]. At age one year we
ssessed cytokine responses induced by BCG given at birth and by
etanus immunisation given at 6, 10 and 14 weeks of age. While
here is no major concern regarding efﬁcacy of tetanus immu-
isation, assessment of responses to tetanus toxoid (TT) allowed
s to investigate effects on a vaccine that elicits a more type-2
iased response than BCG, and that is given later in infancy. The
mpactof theanthelminthic interventiononcytokine responseshas
een reported elsewhere [20]. We here describe planned observa-
ional analyses conducted to investigate factors affecting the infant
esponse to immunisation during pre-natal and early post-natal
ife.
. Materials and methods.1. Study design
The study was a randomised, double-blind, placebo-controlled
rial of albendazole or praziquantel treatment during pregnancy,
Fig. 1. Study29 (2011) 247–255
with a 2×2 factorial design, resulting in fours arms, albenda-
zole plus praziquantel, albendazole plus placebo for praziquantel,
praziquantel plus placebo for albendazole and double placebo
[ISRCTN32849447] [19]. Using the trial birth cohort, this obser-
vational analysis examined associations between infant cytokine
responses to BCG and tetanus immunisation, and pre- and
post-natal exposure to helminths, other co-infections and other
potentially related factors.
2.2. Setting and participants
The study area comprised Entebbe Municipality and surround-
ing communities (Fig. 1).Women from the study area, in the second
or third trimester of pregnancy, were recruited at Entebbe Hospi-
tal antenatal clinic between 2003 and 2005 if planning to deliver
in the hospital and willing to know their HIV status; they were
excluded for haemoglobin <8g/dl, clinically apparent severe liver
disease, diarrhoeawith blood in stool, history of adverse reaction to
anthelminthics, abnormal pregnancy, or if already enrolled during
an earlier pregnancy.
The study was approved by ethical committees of the Uganda
Virus Research Institute and London School of Hygiene & Tropi-
cal Medicine, and by the Uganda National Council for Science and
Technology. All participants gave written informed consent.
2.3. Procedures
Socio-demographic details were recorded and blood and stool
samples obtained prior to treatment of women with the trial
intervention (single dose albendazole 400mg or matching placebo
and praziquantel 40mg/kg or matching placebo). The interven-
tion medication was given during the second or third trimester of
pregnancy (according to when the women presented at the clinic
and completed screening procedures). Women received standard
antenatal care includinghaematinics and intermittentpresumptive
treatment for malaria with sulfadoxine–pyrimethamine. Tetanus
immunisation, up to a maximum of three doses, was given during
area.
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regnancy unless the woman had completed a total of ﬁve doses
uring previous pregnancies. HIV-positive women were offered
ingle dose nevirapine for themselves and their infants for pre-
ention of mother-to-child HIV transmission [21]. Six weeks after
elivery all women received treatment with both albendazole and
raziquantel. Infants receivedBCGandpolio immunisation at birth,
olio, diphtheria, pertusis, tetanus, hepatitis B and Haemophilus
nﬂuenzae immunisation at 6, 10 and 14 weeks of age, and measles
mmunisation at nine months. Infant illnesses were treated at the
tudy clinic. At age 12 months blood was obtained from infants;
eight and height were measured.
Vaccines were those provided by the Ugandan National Medical
tores: during the study period, BCG vaccine was provided from
hree suppliers: BB-NCIPD Ltd., Bulgaria, Serum Institute of India,
ndia and Statens Seruminstitut, Denmark.
.4. Diagnostic tests, parasitology and haemotology
HIV serologywasperformed formothers, and for infants aged18
onths, by rapid test algorithm [22]. HIV DNA PCR was performed
20], and HIV load measured (Bayer Versant branched DNA assay
ersion 3.0; Bayer HealthCare, Leverkusen, Germany), for infants of
IV-positive mothers at age six weeks. Stools were examined for
elminth ova by Kato-Katzmethod [23] and by culture for Strongy-
oides [24]; blood samples were examined by modiﬁed Knott’s
ethod formicroﬁlariae [25] andby thickﬁlmformalariaparasites,
s previously described [22].
Clinicalmalariawas deﬁned as fever≥37.5 ◦Cplus parasitaemia.
symptomatic malaria was deﬁned as parasitaemia in the absence
f fever or other symptoms of malaria.
.5. Immunological assays
Primary outcomes were infant immune responses to mycobac-
erial antigen and to TT, taken to represent the response to BCG
nd tetanus immunisation, respectively. We examined stimulated
ytokine production in a whole blood assay, as described else-
here: IFN- was measured to assess type 1 responses; IL-5 and
L-13 were measured to assess type 2 responses (since IL-4, the
allmark of the type 2 response, is seldom detectable in culture
upernatant, particularly following stimulationwithmycobacterial
ntigen) and IL-10 was measured to assess regulatory responses
26]. Brieﬂy, unseparated, heparinised blood was diluted to a ﬁnal
oncentration of one-in-four using RPMI supplemented with peni-
illin, streptomycin and glutamine, plated in 96-well plates, and
timulated with crude culture ﬁltrate protein from M. tuberculo-
is (cCFP; 5g/ml) (kindly provided by John Belisle, University of
olorado, Fort Collins, USA), TT (12 Lf/ml; Statens Seruminstitut,
enmark), phytohaemagglutinin (PHA; 10g/ml; Sigma, UK), or
eft unstimulated. Supernatantswereharvestedonday6and frozen
t −80 ◦C until analysed.
Cytokine concentrations in supernatants were measured by
LISA (Becton Dickinson, UK). Test responses were regarded as
ositive if greater than the mean plus two standard deviations
f negative control results for all assays: IFN->73pg/ml; IL-
> 34pg/ml; IL-13>18pg/ml; IL-10>48pg/ml. Values below the
ut-off were set to zero. Cytokine production in unstimulated test
ells was subtracted from concentrations produced in response to
timulation. Assays were performed after all samples had been col-
ected, in a randomised sequence, to avoid confounding of secular
rends with variations in assay performance..6. Study size
The study size was determined for the trial objectives, rather
han for this analysis. It was anticipated that, with recruitment of29 (2011) 247–255 249
2500 women, at least 1594 infants would be assessed at one year;
this would give 80% power with p<0.05 to detect differences of
0.11 log10 in cytokine responses for exposureswith twoequal-sized
categories [19].
2.7. Statistical analyses
The objective of this observational analysis was to determine
socio-demographic, maternal and infant factors associated with
cytokine responses following BCG and tetanus immunisation.
Socio-demographic factors were maternal age, maternal educa-
tion (categories none, primary, secondary or tertiary), household
socioeconomic status (a six-level score based on building materi-
als, number of rooms, items owned) and location of residence (by
zone, Fig. 1). Maternal factors were the three commonest maternal
helminth infections (hookworm, Mansonella perstans, Schistosoma
mansoni), maternal asymptomatic malaria parasitaemia (Plasmod-
ium falciparum) and maternal immunisation status (absence or
presence of a maternal BCG scar; number of documented doses
of tetanus immunisation during pregnancy). Infant factors were
gender, birth weight, anthropometric scores at age one year
(weight-for-age, height-for-age andweight-for-height [27]), infant
malaria (current, asymptomatic malaria on the day of the assay;
number of documented clinical malaria episodes in the preceding
year) and HIV status (based on maternal and infant serology, and
infant PCR at age six weeks: unexposed, exposed-uninfected, or
infected).
Cytokine responses showed skewed distributions, with a dis-
proportionate number of zero values, as has commonly been
observed for immunoepidemiological data and, in particular, for
the use of whole blood stimulation and cytokine response assays
[28–30]. Results were transformed to log10(cytokine concentra-
tion+1) andanalysedby linear regressionusingbootstrappingwith
10,000 iterations to estimate standard errors and bias-corrected
accelerated conﬁdence intervals [29]. Regression coefﬁcients and
conﬁdence limits were back-transformed to express results as
ratios of geometric means. Crude associations were ﬁrst exam-
ined. The following strategy was then employed to investigate
multivariate associations. A simple hierarchical causal diagramwas
developed (Fig. 2). Socio-demographic factors were considered as
potential confounders for the relationship between each expo-
sure and cytokine response, and maternal co-infections (malaria
parasitaemia and helminths) were considered as potential con-
founders for each other and for infant exposures. Treatment with
albendazolewasconsideredasapotential effectmodiﬁer formater-
nal hookworm and M. perstans infections, and treatment with
praziquantel for S. mansoni infection. Infant co-infections were
considered as potential confounders for infant anthropometric
exposures. For all exposures, any remaining variable that showed a
crude association with the outcome and that was not on the causal
pathway between the exposure of interest and the outcome was
included in the model to improve the precision of the estimated
effects. BCG supplier (for analyses of response to BCG) and assay
characteristics (antigen batch and lymphocyte count) were also
considered in all models.
3. Results
3.1. ParticipantsThe ﬂow of participants through the study has been described
elsewhere [20] and is summarised in Fig. 3. Of 2507 women
enrolled, information was obtained on 2345 live births. Results
from 1542 babies (singletons or older twins or triplets) were avail-
able at one year. Of these, 36 had not received BCG immunisation
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Socio-economic status        Maternal education Location of residence             Maternal age
Maternal BCG scar
Maternal co-infectionsMaternal mycobacterial infection
Birth weight
Infant co-infections Infant growth and nutrition
Infant gender
Assay characteristics
BCG source
Cytokine responses 
to cCFP and TT
Maternal tetanus immunisation
Socio-demographic factors
Fig. 2. Causal diagram.
Not resident in Entebbe/Katabi (n=6243)
Unwilling to receive HIV result (n=1186)
Unwilling to participate (n=874)
Incomplete screening procedures (n=646)
Already had baby in study (n=115)
Pregnancy not normal (n=83)
Not planning to deliver in hospital (n=37)
Haemoglobin <8 g/dl (n=17)
Diarrhoea with blood in stool (n=15)
Adverse reaction to anthelminthics (n=5)
Clinically apparent severe liver disease (n=0)
Other/ no reason stated (n=47)
Enrolled twice (n=8)
Assessed for 
eligibility 
(n=11,783)
Blood sample at 
one year 
(n=1,542)
Haemoglobin<8 (n=2)
Lost to follow-up before delivery (n=131)
Miscarriage (n=18)
Stillbirths (n=44)Live births* 
(n=2,345)
Died or lost to follow-up before 1 year (n=230)
Still in follow-up but did not attend 1 year visit (n=444)
Seen at one year but no sample available (n=111)
Younger twin/triplet excluded from analysis (n=16)
Incomplete assay (n=2)
Enrolled
(n=2,507)
Analysed for 
responses to BCG 
(n=1,506)
Analysed for 
responses to TT  
(n=1,433)
Incomplete tetanus immunisation (n=109)No BCG at Entebbe hospital (n=36)
* Includes multiple births
Fig. 3. Flow of participants through the study.
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erium tuberculosis among infants who received BCG immunisation at birth. (B) Resp
uring infancy. The central line represents the median; boxes represent 75th and
utside values.
t Entebbe Hospital and 109 had incomplete tetanus immunisa-
ion: therefore1506 infantswere included inanalyses for responses
ollowing BCG immunisation, and 1433 for tetanus immunisation.
As previously reported, the median maternal age was 23 years;
ost women (54%) had either primary or no formal education [31].
he majority (41%) lived in Entebbe Municipality, 28% in Manyago
nd Kabale, 11% Katabi roadside, 9% Katabi rural and 11% Kiggungu
shing village (Fig. 1). Sixty-eight percent had at least one helminth
nfection; 44% had hookworm, 21% M. perstans and 18% S. mansoni;
1% had asymptomatic malaria at enrolment; 12% had HIV infec-
ion [31]. Sixty percent had a BCG scar; 22%, 61% and 17% had zero,
able 1
rude associations with response to crude culture ﬁltrate proteins of Mycobacterium tube
Factora IFN-
Socio-demographic characteristics
Household socioeconomic status 1.02 (0.94, 1.11)
Mother’s education 1.03 (0.88, 1.19)
Mother’s age at enrolment 1.01 (0.99, 1.03)
Location of residence
Entebbe Town, urban 1
Manyago and Kabale, semi-urban 1.07 (0.82, 1.37)
Kigungu, ﬁshing village 1.10 (0.76, 1.51)
Katabi, roadside 1.15 (0.76, 1.66)
Katabi, rural 0.91 (0.54, 1.40)
Maternal characteristics
Maternal hookworm infection at enrolment 0.89 (0.71, 1.11)b
Maternal S. mansoni infection at enrolment 0.80 (0.58, 1.07)
Maternal M. perstans infection at enrolment 0.95 (0.72, 1.21)
Maternal malaria parasitaemia at enrolment 0.88 (0.57, 1.23)
Maternal BCG scar 0.85 (0.68, 1.06)
Infant characteristics
Infant female 0.77 (0.63, 0.95)
Birth weight 1.21 (0.97, 1.53)
Weight for age z score at 1 year 1.10 (1.01, 1.21)
Height for age z score at 1 year 1.06 (0.97, 1.16)
Weight for height z score at 1 year 1.09 (0.99, 1.19)
Infant malaria (current, asymptomatic) 0.47 (0.27, 0.75)
Number of malaria episodes in infancy 0.97 (0.85, 1.09)
Infant HIV status
Unexposed 1
Exposed, uninfected 1.00 (0.64, 1.44)
Infected 0.06 (0.02, 0.22)
ata are for 1506 children who received BCG immunisation at Entebbe Hospital. Conﬁden
a Missing values: maternal BCG scar, 54; maternal malaria, 26; maternal education, 3;
eight for age, 2; height for age, 16; weight for height z scores, 17; infant malaria parasit
b Effect ofmaternal hookwormon IFN- responsemodiﬁed bymaternal treatmentwith
0.88, 1.61).
c Effect of maternal M. perstans on IL-10 response modiﬁed by maternal treatment with
1.27, 2.19).g infants aged one year. (A) Responses to crude culture ﬁltrate proteins of Mycobac-
to tetanus toxoid among infants who received three doses of tetanus immunistaion
centiles; whiskers represent upper and lower adjacent values and dots represent
one and two or more recorded doses of tetanus immunisation dur-
ing pregnancy, respectively. Women whose infants had cytokine
results available at one year were older, of higher socioeconomic
status and less likely to live in Katabi, and had lower prevalence of
helminths, asymptomatic malaria and HIV infection during preg-
nancy, than those without results (data not shown).Among infants with results at one year, 50% were female; the
mean birth weight was 3.18kg; at one year the mean weight-for-
age z score was −0.33, mean height-for-age z score −0.84 and
mean weight-for-height z score 0.10; 6% had asymptomatic P. fal-
ciparum malaria; 9% were HIV-exposed-uninfected and 1% were
rculosis in infants who received BCG immunisation at birth.
IL-5 IL-13 IL-10
1.05 (0.97, 1.15) 1.04 (0.95, 1.14) 0.99 (0.91, 1.07)
0.99 (0.86, 1.15) 1.03 (0.88, 1.21) 0.92 (0.80, 1.05)
1.02 (1.00, 1.03) 1.01 (0.99, 1.03) 1.00 (0.98, 1.02)
1 1 1
1.01 (0.79, 1.29) 0.93 (0.72, 1.21) 1.01 (0.79, 1.27)
1.00 (0.71, 1.44) 0.98 (0.68, 1.39) 1.19 (0.85, 1.60)
0.87 (0.63, 1.27) 1.34 (0.92, 1.92) 1.36 (0.96, 1.83)
0.66 (0.46, 0.99) 0.86 (0.54, 1.35) 1.67 (1.12, 2.30)
0.93 (0.76, 1.15) 1.01 (0.81, 1.26) 0.91 (0.75, 1.10)
0.83 (0.64, 1.08) 0.91 (0.68, 1.20) 0.71 (0.53, 0.93)
0.82 (0.64, 1.04) 0.95 (0.72, 1.23) 1.31 (1.03, 1.63)c
0.61 (0.46, 0.86) 0.81 (0.56, 1.16) 1.33 (0.95, 1.71)
0.77 (0.62, 0.95) 0.77 (0.62, 0.97) 1.00 (0.82, 1.22)
0.74 (0.61, 0.91) 0.79 (0.64, 0.98) 0.85 (0.70, 1.03)
1.17 (0.93, 1.48) 1.27 (0.98, 1.63) 1.14 (0.93, 1.42)
1.09 (1.00, 1.19) 1.04 (0.95, 1.14) 1.09 (1.01, 1.18)
1.10 (1.01, 1.20) 1.08 (0.99, 1.18) 1.05 (0.97, 1.14)
1.05 (0.97, 1.14) 1.00 (0.91, 1.09) 1.07 (0.99, 1.16)
0.43 (0.32, 0.62) 0.48 (0.30, 0.77) 0.97 (0.63, 1.35)
0.84 (0.76, 0.94) 1.00 (0.88, 1.12) 1.09 (0.96, 1.21)
1 1 1
1.00 (0.72, 1.44) 1.12 (0.77, 1.63) 0.87 (0.59, 1.21)
0.33 (0.26, 0.74) 0.16 (0.09, 0.38) 2.20 (1.49, 3.21)
ce intervals not including one are highlighted in bold.
household socioeconomic status, 32; location of residence, 15; birth weight 248;
aemia, 28.
albendazole: albendazole group, GMR=0.67 (0.48, 0.90); placebo groupGMR=1.19
albendazole: albendazole group, GMR=0.97 (0.66, 1.36); placebo group GMR=1.69
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Table 2
Crude associations for infant response to tetanus toxoid after tetanus immunisation at 6, 10 and 14 weeks of age.
Factora IFN-b IL-5 IL-13 IL-10
Socio-demographic characteristics
Household socioeconomic status 1.09 (0.97, 1.23) 1.03 (0.92, 1.15) 1.03 (0.93, 1.14) 0.91 (0.82, 1.00)
Mother’s education 1.22 (1.00, 1.49) 1.22 (1.01, 1.47) 1.15 (0.97, 1.36) 0.88 (0.75, 1.03)
Mother’s age at enrolment 0.98 (0.96, 1.01) 1.00 (0.98, 1.03) 0.99 (0.97, 1.01) 0.99 (0.97, 1.01)
Location of residence
Entebbe Town, urban 1 1 1 1
Manyago and Kabale, semi-urban 0.88 (0.62, 1.22) 0.82 (0.61, 1.13) 0.77 (0.58, 1.04) 0.94 (0.72, 1.23)
Kigungu, ﬁshing village 1.00 (0.61, 1.64) 1.12 (0.72, 1.75) 1.02 (0.67, 1.50) 1.31 (0.90, 1.94)
Katabi, roadside 1.13 (0.67, 1.83) 1.34 (0.84, 2.11) 1.33 (0.86, 1.94) 1.48 (1.01, 2.18)
Katabi, rural 0.92 (0.50, 1.66) 0.61 (0.36, 1.08) 0.65 (0.37, 1.09) 2.00 (1.23, 3.28)
Maternal characteristics
Maternal hookworm infection at enrolment 0.85 (0.65, 1.14) 0.95 (0.73, 1.22)c 0.87 (0.69, 1.10)d 1.17 (0.94, 1.46)
Maternal S. mansoni infection at enrolment 0.88 (0.61, 1.29) 0.97 (0.69, 1.36) 0.96 (0.69, 1.30) 0.81 (0.61, 1.08)
Maternal M. perstans infection at enrolment 0.87 (0.61, 1.24) 1.03 (0.75, 1.44) 0.95 (0.70, 1.27) 1.46 (1.11, 1.95)e
Maternal malaria parasitaemia at enrolment 0.85 (0.52, 1.38) 0.70 (0.45, 1.09) 0.79 (0.51, 1.20) 1.09 (0.74, 1.61)
Number of doses of tetanus toxoid during pregnancy 1.45 (1.18, 1.79) 1.21 (0.99, 1.47) 1.25 (1.05, 1.50) 0.86 (0.72, 1.02)
Infant characteristics
Infant female 0.70 (0.53, 0.93) 0.78 (0.61, 1.01) 0.85 (0.67, 1.08) 0.77 (0.62, 0.95)
Birth weight 1.06 (0.77, 1.47) 1.28 (0.95, 1.69) 1.43 (1.08, 1.87) 0.88 (0.69, 1.13)
Weight for age z score at 1 year 1.11 (0.98, 1.25) 1.19 (1.07, 1.32) 1.20 (1.09, 1.33) 1.04 (0.94, 1.15)
Height for age z score at 1 year 1.10 (0.98, 1.23) 1.14 (1.02, 1.27) 1.22 (1.11, 1.35) 0.89 (0.81, 0.98)
Weight for height z score at 1 year 1.08 (0.96, 1.22) 1.15 (1.03, 1.29) 1.12 (1.01, 1.24) 1.14 (1.03, 1.25)
Infant malaria (current, asymptomatic) 0.45 (0.24, 0.83) 0.32 (0.20, 0.54) 0.45 (0.26, 0.74) 2.73 (1.65, 4.43)
Number of malaria episodes in infancy 0.92 (0.78, 1.08) 0.90 (0.79, 1.05) 0.87 (0.75, 0.98) 1.24 (1.09, 1.41)
Infant HIV status
Unexposed 1 1 1 1
Exposed, uninfected 0.57 (0.34, 0.94) 0.53 (0.35, 0.84) 0.67 (0.43, 1.02) 0.94 (0.64, 1.41)
Infected 0.30 (0.10, 1.00) 0.15 (0.09, 0.59) 0.09 (0.04, 0.25) 0.81 (0.34, 2.64)
Data are for 1433 children who received three doses of tetanus immunisation during infancy. Conﬁdence intervals not including one are highlighted in bold.
a Missing values: maternal doses of tetanus immunisation, 2; maternal malaria, 24; maternal education, 3; household socioeconomic status, 28; location of residence, 15;
birth weight 233; height and weight for height z scores, 12; infant malaria parasitaemia, 26.
b One additional missing value for the IFN- response to tetanus toxoid.
c Effect of maternal hookworm on IL-5 response modiﬁed by maternal treatment with albendazole: albendazole group, GMR=0.70 (0.48, 1.01); placebo group GMR=1.26
(0.87, 1.82).
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IV-infected.Only44of1358 infants examinedhadhelminth infec-
ions at age one year (most common were Ascaris (15 infants),
richuris (12 infants) and Mansonella (eight infants)) so effects of
nfant helminths were not considered in this analysis. Ninety-nine
ercent of infants were breast-fed to age six weeks, and 80% were
till being breast-fed at age one year.
.2. Cytokine responses
Type 1 (IFN-) and regulatory (IL-10) cytokines were domi-
ant in the response to cCFP; following tetanus immunisation,
ype 2 cytokines were more prominent (Fig. 4). Crude associations
etween factors examined and cytokine responses are shown in
ables 1 and 2; multivariate analyses in Tables 3 and 4.
.3. Socio-demographic factors
The infant IFN- and IL-5 response to TT increased with mater-
al education, with adjusted geometric mean ratios (aGMR) (95%
onﬁdence interval (CI)) of 1.25 (1.03, 1.54) and 1.25 (1.04, 1.50)
espectively, while the IL-10 response to TT was inversely associ-
ted with socio-economic status (aGMR 0.90 (0.82, 0.98)).
.4. Maternal factorsMaternal M. perstans infection showed a positive association
ith infant IL-10 production in response to both cCFP (aGMR
.23 (0.99, 1.50) and TT (aGMR 1.36 (1.04, 1.80). Both associations
howedamarked interactionwithmaternal albendazole treatmentalbendazole: albendazole group, GMR=0.61 (0.44, 0.86); placebo group GMR=1.23
albendazole: albendazole group, GMR=0.95 (0.65, 1.43); placebo group GMR=2.17
(interaction p-values 0.02 and 0.001, respectively), being evident
only in the albendazole-placebo group (cCFP aGMR1.57 (1.19, 2.00)
and TT aGMR 1.99 (1.35, 2.97)). No consistent associations were
observed for other species.
Maternal BCG scar was associated with a markedly lower infant
IL-5 and IL-13 responses to cCFP (aGMR 0.76 (0.61, 0.94) and 0.80
(0.64, 1.00)) and a somewhat lower IFN- response (aGMR 0.87
(0.70, 1.09)). An increasing number of doses of maternal tetanus
immunisation during the pregnancywas associatedwith increased
infant IFN- (aGMR 1.44 (1.16, 1.79)) and IL-13 (1.22 (1.01, 1.46)),
and a weak increase in IL-5 (aGMR 1.19 (0.97, 1.44)) responses to
TT.
3.5. Infant factors
Female infants had broadly lower responses for both cCFP and
TT, with aGMRs for each cytokine response ranging from 0.69 to
0.86 (Tables 1–4).
Associations for anthropometric variableswere somewhat vari-
able; after adjustment for confounding, associations remained for
the IL-13 response for TT and IL-10 response to cCFP, which both
showed increased responses for higher scores: IL-13 for TT, birth
weight aGMR 1.43 (1.09, 1.89), weight-for-age z-score at one year,
1.13 (1.01, 1.28), height-for-age z-scoreatoneyear1.13 (1.01, 1.26);
IL-10 for CFP, height-for-age z-score at one year, 1.08 (1.00, 1.17).
Current malaria parasitaemia was strongly associated with
reduced IFN-, IL-5 and IL-13 responses for cCFP (aGMR 0.49 (0.28,
0.80), 0.41 (0.30, 0.60) and 0.46 (0.29, 0.75) respectively), and for
TT (aGMR 0.47 (0.25, 0.85), 0.32 (0.21, 0.53) and 0.50 (0.26, 0.93)
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Table 3
Factors associated with the cytokine response to crude culture ﬁltrate proteins of
Mycobacterium tuberculosis in infantswho received BCG immunisation at birth, after
adjustment for potential confounders and other crudely associated factors.
Cytokine/factor Adjusted GMR (95% CI)a
Interferon-
Maternal hookworm infection
Albendazole treatment group 0.70 (0.50, 0.96)
Albendazole placebo group 1.29 (0.95, 1.76)
Baby female 0.79 (0.64,0.98)
Baby malaria (current, asymptomatic) 0.49 (0.28,0.80)
Baby HIV status
Unexposed 1
Exposed, uninfected 0.96 (0.62,1.36)
Infected 0.06 (0.02,0.23)
Interleukin-5
Maternal BCG scar 0.76 (0.61, 0.94)
Baby female 0.72 (0.58, 0.89)
Baby malaria (current, asymptomatic) 0.41 (0.30, 0.60)
Number of malaria episodes during infancy 0.84 (0.76, 0.95)
Baby HIV status
Unexposed 1
Exposed, uninfected 1.01 (0.71, 1.49)
Infected 0.37 (0.25, 1.00)
Interleukin-13
Maternal BCG scar 0.80 (0.64, 1.00)
Baby malaria (current, asymptomatic) 0.46 (0.29, 0.75)
Baby HIV status
Unexposed 1
Exposed, uninfected 1.09 (0.74, 1.59)
Infected 0.20 (0.09, 0.53)
Interleukin-10
Maternal S. mansoni 0.76 (0.58, 0.97)
Maternal M. perstans
Albendazole treatment 0.93 (0.66, 1.27)
Albendazole placebo 1.57 (1.19, 2.00)
Baby height-for-age z-score at 1 year 1.08 (1.00, 1.17)
Baby HIV status
Unexposed 1
Exposed, uninfected 0.83 (0.58, 1.14)
Infected 2.19 (1.56, 3.15)
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Table 4
Factors remaining associatedwith the cytokine response to tetanus toxoid in infants
who received tetanus immunisation at 6, 10 and 14 weeks of age, after adjustment
for potential confounders and other crudely associated factors.
Cytokine/factor Adjusted GMR (95% CI)a
Interferon-
Maternal education 1.25 (1.03, 1.54)
Number of doses of tetanus toxoid during
pregnancy
1.44 (1.16, 1.79)
Baby female 0.69 (0.52, 0.91)
Baby malaria (current, asymptomatic) 0.47 (0.25, 0.85)
Baby HIV status
Unexposed 1
Exposed, uninfected 0.57 (0.35, 0.94)
Infected 0.35 (0.11, 1.13)
Interleukin-5
Maternal education 1.25 (1.04, 1.50)
Baby malaria (current, asymptomatic) 0.32 (0.21, 0.53)
Baby HIV status
Unexposed 1
Exposed, uninfected 0.51 (0.33, 0.82)
Infected 0.16 (0.10, 0.52)
Interleukin-13
Location of residence
Entebbe Town 1
Manyago and Kabale 0.99 (0.64, 1.47)
Kigungu 0.75 (0.56, 0.99)
Katabi, roadside 1.30 (0.86, 1.92)
Katabi, rural 0.60 (0.35, 1.02)
Maternal hookworm
Albendazole treatment 0.64 (0.45, 0.88)
Albendazole placebo 1.33 (0.95,1.89)
Number of doses of tetanus toxoid during
pregnancy
1.22 (1.01, 1.46)
Birth weight 1.43 (1.09, 1.89)
Weight for age z score 1 year 1.13 (1.01, 1.28)
Weight for height z score 1 year 1.13 (1.01, 1.26)
Baby malaria (current, asymptomatic) 0.50 (0.26, 0.93)
Baby HIV status
Unexposed 1
Exposed, uninfected 0.61 (0.39, 0.95)
Infected 0.09 (0.04, 0.27)
Interleukin-102
Household socioeconomic status 0.90 (0.82, 0.98)
Maternal M. perstans
Albendazole treatment 0.87 (0.60, 1.30)
Albendazole placebo 1.99 (1.35, 2.97)
Baby female 0.78 (0.63, 0.97)
Baby malaria (current, asymptomatic) 2.38 (1.48, 3.80)a Figures are geometric mean ratios of cytokine production, with bootstrap 95%
onﬁdence intervals.
espectively), and with a reciprocal increase in IL-10 responses for
T (aGMR 2.38 (1.48, 3.80)). Previous episodes of malaria during
nfancy showed weaker effects, but a high number of episodes was
ssociated with a reduced IL-5 response to cCFP (aGMR 0.84 (0.76,
.95)) and an increased IL-10 response to TT (aGMR 1.18 (1.03,
.34)).
Associations with infant HIV status differed for cCFP and TT.
or cCFP, HIV-exposed-uninfected infants showed no difference
n response compared to HIV-unexposed infants, but HIV-positive
nfants showed markedly lower IFN-, IL-5 and IL-13 responses
aGMR 0.06 (0.02, 0.23), 0.37 (0.25, 1.00) and 0.20 (0.09, 0.53)
espectively), and higher IL-10 responses (aGMR 2.19 (1.56, 3.15)).
or TT, both HIV-exposed-uninfected infants, and HIV-infected
nfants, showed impaired IFN-, IL-5 and IL-13 responses: HIV
xposed-uninfected, aGMR 0.57 (0.35, 0.94), 0.51 (0.33, 0.82) and
.61 (0.39, 0.95); HIV-infected, aGMR 0.35 (0.11, 1.13), 0.16 (0.10,
.52) and 0.09 (0.04, 0.27); there was no effect on the IL-10
esponse.
. Discussion
In this large birth cohort in Uganda, infant responses to BCG and
etanus immunisation were associated with pre-natal and early
ost-natal exposure to maternal M. perstans co-infection, mater-
al and infant HIV co-infection, and infant malaria. Maternal BCG
car showed associations with the infant response to BCG, and
aternal immunisation with tetanus toxoid during pregnancy wasTotal malaria episodes in infancy 1.18 (1.03, 1.34)
a Figures are geometric mean ratios of cytokine production, with bootstrap 95%
conﬁdence intervals.
associatedwithhigher infant responses to their owntetanus immu-
nisation.
As in any observational analysis, some ﬁndings may be
explained by unmeasured confounders. However, most key fac-
tors identiﬁedwere biological, rather than social or environmental,
and adjustment for measured confounders produced little change
in their effect estimates, suggesting that they are closely linked to
causalmechanisms.Many statistical testswere conducted, so some
apparently “signiﬁcant” ﬁndings could have occurred by chance.
Individual results are therefore treated with caution; rather than
formally adjust for multiplicity, we focus on patterns and consis-
tency of results, and on biological plausibility with reference to
other ﬁndings.
Maternal M. perstans microﬁlaraemia was associated with
enhanced IL-10 responses to both cCFP and TT in the offspring.
This ﬁlarial infection is highly prevalent in Africa and central
South America, but usually asymptomatic [32,33]. Adult worms
inhabit serous cavities and microﬁlariae circulate in the blood,
sometimes in thousands per millilitre, the lack of symptoms testi-
fying to this helminth’s potent immunoregulatory properties. Such
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elminth-induced regulation can inﬂuence host responses to unre-
ated antigens and IL-10 may be one key mediator of such effects
12]; among other ﬁlariases, IL-10 responses to tetanus immunisa-
ion have been found to be elevated in adults with asymptomatic
nchocerca volvulus infection [34,35]. Our key observation is that
he non-speciﬁc effect of helminths on this regulatory cytokine
esponse can be transmitted from mother to infant. Notably, infant
FN-, IL-5 and IL-13 responses were not reduced, suggesting
he possibility that protective immune responses may not be
mpaired, and it is possible that the overall impact of exposure to
aternal helminth infection in utero is an enhancement of regu-
atory immune responses rather than suppression of the ability to
ount protective responses to vaccines and pathogens. This might
e broadly beneﬁcial, protecting against excessive inﬂammatory
esponses, including allergy [36,37].
The lack of observed effects of maternal hookworm or S. man-
oni on type 1 and type 2 responses to mycobacterial antigens was
urprising, given our own earlier ﬁndings [38], and those of Mal-
otra and colleagues [18]. However, in Malhotra’s study all women
ad helminth infection: comparisons were made between infants
ensitised and not sensitised to helminth antigens. Our study com-
ared infants ofmothers infected or not infectedwith each species,
n a setting where most women had at least one helminth infec-
ion; moreover, for logistical reasons, a single stool sample was
sed forKatoKatz analysis giving limited sensitivity for diagnosis of
ntestinal helminths [39,40]. Both these factors may have resulted
n underestimation of effects of schistosomiasis and other intesti-
al helminths. However, taken together with the ﬁnding (reported
lsewhere [20]) that anthelminthics during pregnancy had little
ffect on infant responses to cCFP and TT in this study, these results
uggest that maternal helminth infection may not be the major
xplanation for the poor efﬁcacy of BCG immunisation in the trop-
cs. Subsequent acquisition of helminths by the infant may be a
ifferent story [17].
Tetanus immunisation during pregnancy was associated with
nhanced IFN-, IL-13 and (to some extent) IL-5 responses follow-
ng tetanus immunisation of the offspring. These results accord
ith the earlier report of Gill and colleagues [41] and show that
riming of the infant response to TT can be inﬂuenced by immuni-
ation of the mother. This antigen-speciﬁc effect may result from
ransfer of TT across the placenta within an immune complex, util-
sing the immunoglobulin receptor systems involved in transfer of
aternal antibody to the fetus [42–44]. Fetal exposure to antigen
an result in tolerisation, but immune complexes are potent acti-
ators of the immune system, and this may explain why priming
ccurred in this case. The lower response to tetanus immunisation
nHIV-exposed-uninfected infantsmayhave resulted fromreduced
ransfer of maternal antibody and antigen in this group [45,46].
By contrast, presence of a maternal BCG scar showed a nega-
ive association with infant type 2 cytokine response, and (to some
xtent) IFN- response to cCFP following BCG immunisation. This
ay have been a non-speciﬁc effect since maternal BCG scar was
lso associated with reductions in these cytokine responses to PHA
data not shown). The association was not explained by adjusting
or potential confounding factors, and suggests an immunolog-
cal interaction between mother and infant related to maternal
ycobacterial exposure or infection. There is evidence for sen-
itisation to mycobacterial antigens in utero in mouse models
nd in humans [47,48], but tolerisation is also a possibility, and
ould accord with the lower response to mycobacterial antigen
bserved in Malawian, compared to British, infants following BCG
mmunisation [10]. It may be important to investigate the role of
aternalmycobacterial infection, andmaternal immune responses
o mycobacteria, in the infant response to BCG.
Current infant malaria and infant HIV infection were associated
ith broad reductions in IFN-, IL-5 and IL-13 responses. These29 (2011) 247–255
ﬁndings were in keeping with the recognised immunosuppres-
sive effects of these pathogens and thus, incidentally, demonstrate
the ability of this immuno-epidemiological approach to detect
important effects. They contrast with the IL-10-restricted effects of
maternal M. perstans. For malaria, these effects were mainly short-
term, observed only in the presence of current infection; however,
decreased IL-5 cCFP and increased IL-10 TT responses were associ-
ated with both current and previous malaria. It is possible that the
independent association between increased IL-10 TT responses and
household socio-economic status might be mediated by repeated,
unmeasured, exposures to infection.
Consistently lower responses were seen in girls. This shows
that gender differences in immune response are present at
an early age, and could be related to reported gender dif-
ferences in the non-speciﬁc effects of immunisation on infant
mortality [49].
This study examined factors inﬂuencing the cytokine responses
induced by BCG and tetanus immunisation, not their efﬁcacy. In
the case of BCG, it is likely that IFN- is required, although not suf-
ﬁcient for, protective immunity [15], while excessive production
of type 2 cytokines may be detrimental [50]. Excess production
of IL-10 may also be detrimental, if it is associated with suppres-
sion of protective responses, but evidence from the mouse model
suggests that adequate production may be required to prevent a
pathological, inﬂammatory response [51]. Follow up of the cohort
is in progress to determine how the observed responses are related
to rates of M. tuberculosis infection and disease. In the case of
tetanus immunisation, the induction of neutralising antibody is key
to protective immunity [52]; the relationship between observed
effects on cytokine responses and the production of antibody will
be the subjectof further investigation.Fromapublichealthperspec-
tive, our results demonstrate strong effects of current, or recent
infant infections on the infant response to vaccine antigens, and
reinforce the importance of control and treatment of malaria and
HIV infection for the immunological health of mothers and their
children; but suggest that maternal helminth infection may have
little, if any, adverse effect on the outcome of infant immunisation.
Immunisation during pregnancy may enhance the infant response
to selected vaccines, and this, as well as the role of prior mater-
nal BCG immunisation and mycobacterial infection in determining
the infant response to BCG immunisation, needs to be explored in
further research.
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